Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
Basic Trial Information
|Phase IV||Supportive care||Active||18 and over||Mann-Cohen Version 2|
Evaluate the efficacy and safety of using aboBTX-A to improve wound healing prior to Mohs
micrographic surgery and reconstruction for skin cancer of the forehead
Further Study Information
- Outcomes by the Patient and Observer Assessment Scale (POSAS), Visual Analog Scale, and
Patient Satisfaction Survey.
Study consists of 5 clinic visits over approximately 6 months
Have biopsy proven skin cancer on the forehead that is amenable to Mohs surgery
Undergoing elective reconstruction of biopsy proven skin cancer that is amenable to
Mohs surgery with defect size measuring 1.0 cm or greater
If female, not currently pregnant, not currently breastfeeding, no potential for
pregnancy, or if of child-bearing age, agrees to using birth control.
Agrees to not use disallowed concomitant medications (retinoids) and agrees to use
sunscreen in the forehead area for the duration of the study
Current or past history of a neuromuscular disease (such as myasthenia gravis,
amyotrophic lateral sclerosis, Eaton-Lambert syndrome)
History of radiation therapy or chemotherapy
History of keloid or other hypertrophic scar formation
Has used botulinum toxin in the forehead area within one year.
Has used any topical retinoids to the forehead area within the past 4 weeks
Any hypersensitivity to any component of abobotulinumtoxinA (i.e. cow milk protein)
or any previous hypersensitivity to any botulinum toxin A or related product.
Trial Contact Information
Trial Lead Organizations / Sponsors / Collaborators
AboutSkin Dermatology and DermSurgery, PC
- Medicis Pharmaceutical Corporation
- University Hospitals Cleveland Medical Center
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01459666
Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.